An emerging entity: Pancreatic adenocarcinoma associated with a known brca mutation: Clinical descriptors, treatment implications, and future directions

Oncologist

Volumn 16, Issue 10, 2011, Pages 1397-1402

  Lowery, Maeve A ^a   Kelsen, David P ^a   Stadler, Zsofia K ^a   Yu, Kenneth H ^a   Janjigian, Yelena Y ^a   Ludwig, Emmy ^a   D'Adamo, David R ^a   Salo Mullen, Erin ^a   Robson, Mark E ^a   Allen, Peter J ^a   Kurtz, Robert C ^a   O'Reilly, Eileen M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brca1; Brca2; Genetics; Pancreas adenocarcinoma; Parp

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; DOCETAXEL; FLAVOPIRIDOL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXALIPLATIN; PLATINUM COMPLEX; TEMOZOLOMIDE;

ACINAR CELL CARCINOMA; ADULT; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MALE; METASTASIS; ONCOGENE; PANCREAS ADENOCARCINOMA; PANCREAS SURGERY; PRIORITY JOURNAL; SYSTEMIC THERAPY; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; JEWS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS;

EID: 80054820265     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0185     Document Type: Article

References (13)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Hahn SA, Greenhalf B, Ellis I et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003;95:214-221.
3. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J. Natl. Cancer Inst 1999;91:1310-1316.
4. Brose MS, Rebbeck TR, Calzone KA et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365-1372.
5. Lacour RA, Westin SN, Meyer LA et al. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol 2011;121:358-363.
6. Ferrone CR, Levine DA, Tang LH et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 2009;27:433-438.
7. Ashworth A. A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient inDNAdoublestrand break repair. J Clin Oncol 2008;26:3785-3790.
8. Risch HA, McLaughlin JR, Cole DE et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98:1694-1706.
9. Lowery MA, Stadler ZK, Ludwig Miller E et al. Clinical outcomes in pancreatic adenocarcinoma (PAC) in breast cancer (BC) survivors. J Clin Oncol 2010;28(15 suppl):4152.
10. Sandhu SK, Yap TA, de Bono JS. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective. Eur J Cancer 2010;46:9-20.
11. McCabe N, Lord CJ, Tutt AN et al. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly(ADP-ribose) polymerase: An issue of potency. Cancer Biol Ther 2005;4:934-936.
12. Chalasani P, Kurtin S, Dragovich T. Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation. JOP 2008;9:305-308.
13. Edwards SL, Brough R, Lord CJ et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008;451:1111-1115.